30 closest matches · ranked by relevance
Influenza
Primary: Number of Participants in the CD4 Less Than 200/mL Stratum With 4-Fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza…
Dengue Fever · Dengue Hemorrhagic Fever · Human Immunodeficiency Virus
Primary: Percentage of Participants With Unsolicited Systemic Adverse Event (AE) — 0; 0 percentage of participants
Aids, Cdc Group I
Primary: Tolerability and Safety of the Treatment. — 0; 0 participants
Hiv · HIV Infections · AIDS
Primary: Prevalence of HIV Infection — 6 Participants
Depression · HIV Infections · HIV-Associated Cognitive Motor Complex
Primary: Influx Constant (Ki) for 18F-FDOPA PET. — 0.01415; 0.01409; 0.01588; 0.01592 min-1
HIV Infections · Memory
Primary: The Prevalence of Neurocognitive Deficits Among HIV-positive Patients as Defined by the Global Deficit Score Based on the Neuropsychological Testing Battery and to…
Human Immunodeficiency Virus (HIV) Positive
Primary: Number of Participants With Viral Load Suppression — 210; 213 Participants — p=0.220
HIV-1
Primary: Percentage of Participants With Clonal Expansion of Cells With a Predominant OZ1 Insertion Site — 0 Percentage of participants
HIV · Metabolic Syndrome · Osteopenia
Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244
HIV Infection
Primary: Pre- and Post- Interferon Alpha on Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) — 670; 180; 90; 130 # of copies of HIV RNA/million cells
Risk Behavior · Medication Adherence · HIV
Primary: Number of Participants in Each Condition With Optimal ART Adherence — 27; 29 participants
Healthy Donors · HIV Positive
Primary: PRISM HIV O Plus Test Data for Specificity — 10; 15589 participants
HIV-1
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 3 Days After VRC01LS or VRC07-523LS Administration — 7; 6; 0; 3 Participants
Herpes Zoster
Primary: Number of Subjects With Serious Adverse Events (SAEs) — 6; 2 Participants
HIV Infections
Primary: Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) — -1.17; -2.15; -2.31; -0.28 Copies per milliliter…
HIV Infections
Primary: Total Treatment-free Time to Initiation of Permanent HAART — 18; 18 months
Tuberculosis
Primary: Number of Subjects With Grade 3 Solicited Local Symptoms — 1; 0; 1; 0 Participants
HIV Infection
Primary: Grade 3 Adverse Event Related to DermaVir Treatment — 0; 0; 0 participants
Dental Implant
Primary: Number of Implants Functioning in HIV Positive Subjects Compared to HIV Negative Subjects — 28; 25 implants
HIV Infections
Primary: Frequency of Grade 3 or Higher Adverse Events — 0 number of occurrences
Hepatitis B Vaccine
Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants
HIV Infection · Cardiovascular Disease Risk
Primary: Number of Participants Who Stated (by Self-report) That They Had Side Effects — 1; 0; 2; 1 participants
Heart Failure
Primary: Sustained Virologic Response After Treatment — 24 Participants
HIV Infections
Primary: Safety — 22; 3; 0; 18 percentage of participants
HIV INFECTIONS
Primary: Numbers of Treatment Related Side Effects (DLT = Reaction 3 or More) — 0; 0 side effects
HIV Infections · H1N1 Influenza Virus
Primary: The Number of Participants Who Had at Least One Adverse Event (AE) — 118; 11; 8; 0 Participants
HIV Coinfection
Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants
Human Immunodeficiency Virus
Primary: Knowledge and Experiences of Breastfeeding Among Women Living With HIV — 58; 25; 0; 11 Participants
HIV
Primary: Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens. — 93; 77; 70; 80 participants
HIV · AIDS
Primary: Incidence Rate of Malignancies — 513; 3; 238; 20 malignancies per 100,000 person-years — p=<0.001